Fleury (BSP:FLRY3) Short Ratio


BSP:FLRY3 Fleury SA BSP:FLRY3
90 GF Score
Price R$16.42
GF Value R$17.47
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Fleury Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BSP:FLRY3
90GF Score
Fleury SA BSP:FLRY3
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Fleury (BSP:FLRY3) Overvalued in 2026?

Based on GuruFocus' analysis, Fleury stock appears to be undervalued. The current stock price of R$16.42 is trading 6% below its estimated GF Value™ of R$17.47. GuruFocus considers Fleury to be Fairly Valued.

Key valuation signals for BSP:FLRY3:

  • Short Ratio:
  • GF Value™: R$17.47 vs. price of R$16.42 (6% below fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the BSP:FLRY3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fleury Business Description

Address Avenida Morumbi 8.860, 8th floor, Brooklin, Sao Paulo, SP, BRA, 04703-002
Fleury SA is engaged in the provision of medical services in the diagnostic, laboratory support (Lab-to-Lab), infusions, clinical analysis, health management, medical care, orthopedics and ophthalmology, fertility, infusion areas and toxicological exams, among others. The company offers diagnostic medicine through physical service units and mobile diagnostic services for consumers. It also provides diagnostic support services to laboratories and hospitals. In addition, the company operates clinics and services in areas such as infusion therapy, orthopedics, ophthalmology, reproductive medicine, and oncology. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from the Diagnostic Medicine Segment.
90GF Score

Get the complete analysis for BSP:FLRY3

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$16.42
Price
R$17.47
GF Value